On Thursday, Shares of Twitter Inc (NYSE:TWTR), gained 1.64% to $30.32. 36.43 million Shares of the company were exchanged.
The stock is down -45.29% in this year through last close. The stock, as of recent close, has shown weekly upbeat performance of 22.85% which was maintained at 11.55% in 1-month period.
A Berlin startup that assists women track their menstrual and fertility cycles has secured funding from investors counting an early backer of Twitter Inc. and SoundCloud Ltd., according to Bloomberg.
New-York based Union Square Ventures LLC and London’s Mosaic Ventures are leading a $7 million investment round in BioWink GmbH, maker of the Clue health app that has 2 million users in 180 countries. Clue will use the money to add new product features, hire staff, further push growth and enter more markets, it said.
“Clue has cracked the code of how to get women to understand and share data about their well-being and at the same time create value for every user,” said Albert Wenger, a partner at Union Square, which manages $1 billion across six funds and has invested in Twitter and music-distribution service SoundCloud. “It has the network effect: As you have more users, the service gets more valuable.”
Clue lets users enter data such as moods, body temperature and sexual activity to analyze and predict their period, fertile windows and premenstrual syndrome, using scientific guidelines. Women’s health apps are the second-largest market in the health and fitness category by downloads after running apps, Wenger said. Clue’s competitors comprise San Francisco-based Glow Inc., started by PayPal Holdings Inc. co-founder Max Levchin, which says it has assisted 50,000 women get pregnant. Bloomberg Reports
Twitter, Inc. operates as a global platform for public self-expression and conversation in real time. It offers various products and services for users, counting Twitter that allows users to create, distribute, and discover content; and Vine and video, a mobile application that enables users to create and distribute short looping videos.
Shares of Regions Financial Corp (NYSE:RF), inclined 0.60% to $9.27, during its last trading session.
In the last trading session, the stock moved on low volume, trading at a volume of 15.35 M as compared to its average daily volume of 16.10 million shares.
Regions Bank and Fundation Group LLC recently declared a contract that will combine the strengths of one of the nation’s largest full service banks with that of a leading online lender to provide small businesses with a first of its kind, coordinated delivery of lending solutions.
Small business owners looking to grow and expand, or to better manage cash flow, will have the option to access Fundation’s online application directly from the Regions.com website. This new co-branded online customer experience will allow small businesses to expedite their loan applications for Regions lending products or elect to apply for a Fundation loan.
Fundation offers a streamlined online loan application with a high-touch concierge service to offer loan applicants valuable information and insight about the loan process and their loan application. Small businesses can apply for a loan in less than 10 minutes and loans can be funded in three days. To apply, customers simply visit Regions.com/smallbusiness and are directed through a link from Regions.com to Fundation’s online application.
Regions Financial Corporation, together with its auxiliaries, provides banking and bank-related services to individual and corporate customers in the United States.
At the end of Thursday’s trade, Shares of VIVUS, Inc. (NASDAQ:VVUS), inclined 9.89% to $2.00.
It traded in a range of $1.92 and $2.25, exchanging hands with 11.58 million shares.
VIVUS, Inc. (VVUS) a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea and sexual health, declared that its Board of Directors has determined that it expresses no opinion and remains neutral toward the unsolicited tender offer by IEH Biopharma LLC, a Delaware limited liability company and wholly-owned partner of Icahn Enterprises Holdings L.P. (together, the “Icahn Group”), to purchase any and all of VIVUS’s 4.50% Convertible Senior Notes due 2020.
The Company noted that its Board believes each noteholder should make their own decision as to whether to tender in connection with the Icahn Group’s unsolicited tender offer based on the noteholder’s particular circumstances. It further indicated that its Board believes the determination is a financial decision to be made by each noteholder based on the terms of the tender and the cash price being offered by the Icahn Group. Accordingly, the Board concluded that it would be appropriate to remain neutral as to whether the noteholders should or should not tender the notes.
The Board, however, strongly urges the Company’s noteholders to consider carefully all aspects of the Icahn Group’s offer before deciding for themselves whether to tender.
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
